| Name | Title | Contact Details |
|---|
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Immune-Onc Therapeutics, Inc. is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients.
Quark Pharmaceuticals is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novel therapeutics for metabolic and endocrine disorders
Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.